Association between polymorphisms in angiogenesis‐related genes and the prognosis of classical Hodgkin lymphoma

Abstract

Ding, W., LaPlant, B.R., Call, T.G., Parikh, S.A., Leis, J.F., He, R., Shanafelt, T.D., Sinha, S., LeRademacher, J., Feldman, A.L., Habermann, T.M., Witzig, T.E., Wiseman, G.A., Lin, Y., Asmus, E., Nowakowski, G.S., Conte, M.J., Bowen, D.A., Aitken, C.N., Van Dyke, D.L., Greipp, P.T., Liu, X., Wu, X., Zhang, H., Secreto, C.R., Tian, S., Braggio, E., Wellik, L.E., Micallef, I., Viswanatha, D.S., Yan, H., ChananKhan, A.A., Kay, N.E., Dong, H. & Ansell, S.M. (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 129, 3419–3427. Jain, N., Basu, S., Thompson, P.A., Ohanian, M., Ferrajoli, A., Pemmaraju, N., Cortes, J.E., Estrov, Z., Burger, J.A., Neelapu, S.S., Lopez, W., Thakral, B., Bueso-Ramos, C.E., Blando, J., O’Brien, S.M., Kantarjian, H.M., Allison, J., Keating, M., Sharma, P. & Wierda, W.G. (2016) Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial. Blood, 128, 59–59. Nayak, L., Iwamoto, F.M., LaCasce, A., Mukundan, S., Roemer, M.G.M., Chapuy, B., Armand, P., Rodig, S.J. & Shipp, M.A. (2017) PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood, 129, 3071–3073. Parikh, S.A., Kay, N.E. & Shanafelt, T.D. (2014) How we treat Richter syndrome. Blood, 123, 1647–1657. Richter, M.N. (1928) Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. American Journal of Pathology, 4, 287. Rogers, K.A., Huang, Y., Ruppert, A.S., Salem, G., Stephens, D.M., Heerema, N.A., Andritsos, L.A., Awan, F.T., Byrd, J.C., Flynn, J.M., Maddocks, K.J. & Jones, J.A. (2018) A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. British Journal of Haematology, 180, 259–266. Rossi, D., Spina, V., Deambrogi, C., Rasi, S., Laurenti, L., Stamatopoulos, K., Arcaini, L., Lucioni, M., Rocque, G.B., Xu-Monette, Z.Y., Visco, C., Chang, J., Chigrinova, E., Forconi, F., Marasca, R., Besson, C., Papadaki, T., Paulli, M., Larocca, L.M., Pileri, S.A., Gattei, V., Bertoni, F., Foa, R., Young, K.H. & Gaidano, G. (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, 117, 3391–3401. Tsimberidou, A.M., O’Brien, S., Khouri, I., Giles, F.J., Kantarjian, H.M., Champlin, R., Wen, S., Do, K.A., Smith, S.C., Lerner, S., Freireich, E.J. & Keating, M.J. (2006) Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. Journal of Clinical Oncology, 24, 2343–2351. Younes, A., Brody, J., Carpio, C., Lopez-Guillermo, A., Ben-Yehuda, D., Ferhanoglu, A.B., Nagler, A., Ozcan, M., Avivi, I., Bosch Albareda, F., Caballero Barrig on, M.D., Masood, A., Streit, M., Alvarez, J., Ceulemans, R., Kharabi Masouleh, B., Balasubramanian, S., Schaffer, M., Wang, S.-S., Fourneau, N. & Jurczak, W. (2017) Safety and efficacy of the combination of ibrutinib and nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia. Blood, 130, 833–833.